Shuanglu Pharmaceutical: The stock has deviated from the value by more than 20% for three consecutive days, with no undisclosed matters that should be disclosed.

Double Egret Pharmaceuticals announced that the company's stock price had a deviation of more than 20% for three consecutive trading days on June 29th, June 30th, and July 1st, 2026, which was considered abnormal stock trading fluctuations. After verification, the company's previous disclosure information does not need to be corrected or supplemented. No undisclosed major information that may affect the stock price was found from public media reports. The company's operations are normal, and both internal and external environments have not changed. There are no major matters that should have been disclosed but were not disclosed. The controlling shareholder and the actual controller did not buy or sell the company's stock during the abnormal fluctuations. Investors are reminded to pay attention to the risks of performance fluctuations due to changes in pharmaceutical industry policies.